Closing the Evidence Gap: Why Life Stage Matters in Clinical Validation

Menopause is finally having a cultural reckoning.

Once whispered about or dismissed, it’s now being discussed openly, honestly, and without apology—bringing long-overdue attention to the emotional, physical, and visible changes that come along with it. This cultural shift is something I appreciate, not just as a scientist and clinical researcher but as someone living through perimenopause. Women are showing up for themselves and for one another, demanding better understanding and better care.

As this conversation gains momentum, it raises a critical question: If we recognize how transformative life stages can be, shouldn’t our science reflect that reality too?

Clinical research needs a more nuanced approach to incorporate the role of demographic variability in shaping health outcomes. Despite this, diversified clinical programs have not increased substantially,¹ ultimately limiting how well trial results reflect the real-world patient populations they are intended to serve.

This fact underscores an important issue: We cannot always generalize findings from one demographic to another, as we know these variables can meaningfully affect efficacy and safety. Women are not simply biologically smaller versions of men—they may react differently to medications or even doses of those medications; similarly, during postpartum and even perimenopause, women will have unique biological needs and respond differently from how they would during other life stages.

Holding clinical research to a higher standard means designing studies that reflect their intended populations—intentionally recruiting underrepresented groups—leading to stronger, more meaningful insights, clearer guidance, and more credible outcomes within those populations.

Yet as I noted in my last piece,² when we look at the supplements industry, most research is limited, variable in quality, or met with skepticism.

A life stage, whether it’s perimenopause or postpartum, comes with distinct biological, emotional, and behavioral shifts. Nutritional needs evolve, and supplements designed to support specific outcomes must be studied not only in the population they are intended for, but also within the life stage they aim to address, to capture their true biological impact.

Clinical testing life-stage-based products requires intentionality. Traditional testing models can miss critical nuances if participants are not accurately representative of the stage being addressed. Regulatory and scientific standards also increasingly emphasize the importance of representative study populations, and population-specific evidence elevates supplement research beyond generalized, one-size-fits-all data. For instance, studying supplements specifically in perimenopausal women ensures that benefits are real and aligned with the unique physiology of women experiencing menopause; it can also help identify outcomes that matter most during this time of life (such as changes in hair health, metabolism, and overall well-being).

So it raises the questions:

• How can we provide perimenopausal or menopausal women assurance that a product is designed for them, especially among a community in whom research is more limited?
• How can we help postpartum women feel confident that what they’re taking is not only safe when used as intended but also clinically tested and efficacious in women adjusting to hormonal shifts and life with a new baby?
• How can we show aging men what actually supports health span based on evidence from peers in their age group?

Life-stage-specific clinical research is about relevance, not oversegmentation. By evaluating products in people who are actively living the experience, feedback captures real-world realities, sensitivities, and expectations. It allows researchers to ask better questions, measure outcomes that matter for those populations, and deliver trusted results. Importantly, it encourages rigor over assumptions and evidence over extrapolation.

Health doesn’t exist in a vacuum, and research shouldn’t either. If meaningful innovation starts with meaningful science, then it’s time to ask why life stages experienced by so many remain overlooked in the studies meant to serve them.

The path forward is clear. If science is meant to serve people, it must reflect how people actually live and change over time. Investing in life-stage-specific clinical research isn’t just good science; it’s essential to building products and systems worthy of long-term trust.

Reference

1. Gross AS, Harry AC, Clifton CS, Della Pasqua O. Clinical trial diversity: an opportunity for improved insight into the determinants of variability in drug response. Br J Clin Pharmacol. 2022;88(6):2700-2717. doi:10.1111/bcp.15242
2. Raymond I. The paradox in supplement research. Nutritional Outlook. January 29, 2026. Accessed May 4, 2026. https://www.nutritionaloutlook.com/view/the-paradox-in-supplement-research